A new editorial paper titled “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma” has been published in Oncotarget.

In their new editorial, researchers Kuniko Horie and Satoshi Inoue from Saitama Medical University and Tokyo Metropolitan Institute for Geriatrics and Gerontology discuss renal cell carcinoma (RCC)—a major adult kidney cancer, which is often incidentally discovered as an asymptomatic disease on imaging in the developed countries.

RCC has the most fatal disease among urological cancers, as a recent 5-year relative survival rate in the U.S. (2009–2015) is less than 80%. While RCC is known as a cancer resistant to chemo- and radiotherapies, the prognosis of RCC has been remarkably improved after the clinical application of tyrosine kinase inhibitors (TKIs) and immunotherapy.

The rationale for the efficacy of TKIs in RCC is mainly based on the angiogenetic status, particularly in clear cell RCC (ccRCC) that is the most common type of RCC (70–75% of RCC), in which the loss of function mutation of Von Hippel-Lindau (VHL) tumor suppressor gene activates hypoxia inducible factor (HIF) and vascular endothelial growth factor (VEGF) pathways.

The first-line TKIs that predominantly target VEGF receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) (e.g., sunitinib and sorafenib) have been clinically used since late 2000s, and the second-line TKIs such as cabozantinib, which targets more receptor tyrosine kinases including MET and TAM kinases as well as VEGFR, have been further applied to the treatment of advanced RCC since early 2010s in which the first-line TKIs are ineffective.

“In our recent study, we established a panel of patient-derived ccRCC spheroid cultures with the enhancement of cancer stemness gene signature including DPP4. Focusing on TKI sunitinib sensitivity, we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells,” the researchers explain.

Provided by
Impact Journals LLC

There are now many more days, where I feel like giving up on fighting the cancer culture in this country. SimPal is incredibly busy and I can feel the change we are making daily. In my early days I could see some wins for people affected by cancer. But not now! Politicians, totally disinterested. NHS England fighting with it’s own people. Individuals, inside or out of the service, with next to no chance of making a difference on their own now. I’m totally bored with most large charities, bringing up the same issues, I’ve seen more than 10 years ago, and still begging for more money. Even though they are continuing on the circle of failure.

cancer casts a long, dark shadow over the UK today. As incidence rates continue to rise, our overburdened health system struggles to keep pace. Years of neglect have left cancer care fragmented, underfunded and woefully unprepared. Unless we urgently prioritize reform, this burgeoning crisis threatens to eclipse all other concerns.

Already, outcomes lag far behind other nations. The UK has the lowest cancer survival rates among comparable Western countries. And the gap is only widening, with progress stalled for a decade as European neighbours surge ahead. Despite pouring billions into cutting-edge research, we fail where it matters most – aiding those currently battling the disease.

Behind the statistics lie real people betrayed. Patients denied swift access to ground breaking innovations. Families shattered when timely treatment could have made all the difference. And an exhausted, demoralized workforce battling valiantly against the odds. Without recognition of these urgent human costs, cancer will continue its insidious spread through society.

Why has it come to this? Firstly, while research breakthroughs provide hope, many now languish unused. Rigid barriers prevent rapid translation into clinical practice. Patients most in need are last to benefit, as proven treatments gather dust awaiting formal approval. We must find faster pathways to get innovations where they matter most – into hospitals and clinics across the nation.

Secondly, early diagnosis remains a key stumbling block. GPs face ever-growing demands, leaving little time to suspect cancer amidst a 10-minute appointment. Public awareness campaigns can encourage vigilance for warning signs. But we also need systematic changes – better diagnostic equipment in local practices, prompt specialist referral processes, and strategies to identify those at highest risk. The difference between Stage one and Stage three cancer, is the difference between life and death.

Workforce shortages also hamper efforts, with chronic understaffing now the status quo. Vital posts sit vacant for months, patient loads grow untenable, and staff burnout fuels an exodus from the cancer field. Without Valuing those providing care, we cannot hope to retain them.

Finally, and most critically, years of austerity have left services emaciated. Budgets tighten, equipment ages, and rising need outpaces capacity. Patients now wait months where weeks once sufficed. The system creaks under unsustainable strain – a superficial bandage on a gaping wound.

What will continued disregard for these realities entail? Projections forecast a 63% rise in cancer cases over the next two decades. Our cancer infrastructure is already bursting at the seams. Without urgent investment in staff, equipment and facilities, this influx of new cases will trigger total collapse.

Rising demand will extend delays even further as exhausted resources are stretched beyond breaking point. Patients will have outcomes decided the day they receive their cancer diagnosis – not by tumour biology but by postcode and luck in timing.

Ultimately, the real victims are not statistics but human beings. Sons and daughters, partners and parents, valued members of every community. Behind every percentage are shattered lives and devastated families. If outcomes worsen, hundreds of thousands more will lose loved ones each year.

We stand at a crossroads today. Further neglect and underfunding set society on a path toward tragedy on an unprecedented scale. Only through collective action can we alter course – championing reform, embracing innovation, investing in clinical care, and making cancer the priority it deserves to be. The time has come to step out of the shadow.

With comprehensive modernization, improved prevention and early diagnosis, the UK can still deliver world-leading cancer care to meet this growing threat. But the hour is late, and the storm is nearing. We must come together, stand up and say enough – no more lip service, no more half measures. The time for change is now.

I haven’t come this far to turn back now! The odds for me to survive were dreadful, but here I am. I will continue to fight, for future generations who deserve better. Not being stuck on life limiting waiting lists, dying whilst waiting for care. As always, these are my opinions, based on personal experiences. Please feel free to share your own, below.

Related

Para muchas personas, las hamburguesas asadas o las verduras crujientes son los platos favoritos. Pero, ¿comer alimentos a la parrilla o asados o alimentos cocinados a altas temperaturas puede afectar al riesgo de desarrollar cáncer?

Se encuentran varios tipos de sustancias químicas en carnes a la parrilla, asadas y bien cocidas, así como en algunos alimentos a base de plantas horneados, tostados o fritos cuando se cocinan a altas temperaturas. Aquí encontrará información sobre cuáles son estas sustancias químicas, cómo pueden afectar al riesgo de desarrollar cáncer y qué puede hacer para reducir su exposición a sustancias químicas al cocinar.

¿Cuáles son las sustancias químicas que se encuentran en los alimentos a la parrilla o en los alimentos cocinados a altas temperaturas?

Dos sustancias químicas, los hidrocarburos aromáticos policíclicos (HAP) y las aminas heterocíclicas (AHC), se desarrollan de forma natural al cocinar carne. Cuando cocina carne, la grasa y el jugo gotean en la bandeja de goteo de la parrilla, lo que provoca llamas y humo que contienen HAP. Esto, a su vez, recubre la carne con HAP. Los HAP también se encuentran en los alimentos ahumados, el humo del tabaco y el escape del auto. Mientras tanto, las AHC se producen de forma natural cuando se calienta carne, como carne de res, pollo, cerdo o pescado, a altas temperaturas.

Otra sustancia química llamada acrilamida se desarrolla de forma natural al cocinar, tostar o freír papas u otros alimentos a base de plantas a altas temperaturas. La acrilamida es una sustancia química que se forma cuando los azúcares reaccionan con aminoácidos en los alimentos que se hornean, fritan o tuestan. Puede encontrar acrilamida en papas fritas u horneadas, galletas y otros productos horneados, y café. El agua potable y el humo del tabaco también contienen acrilamida, y las personas que fuman tienen niveles más altos de biomarcadores de acrilamida en la sangre que los no fumadores, según un estudio de 2010 sobre Perspectivas de salud medioambiental (en inglés).

Si desea obtener más información sobre qué alimentos contienen acrilamida, la Food and Drug Administration (FDA, Administración de Alimentos y Medicamentos) de los EE. UU. publica en línea el contenido de acrilamida en miles de alimentos (en inglés).

¿Pueden los HAP y las ACH causar cáncer?

En estudios con animales, los roedores que siguieron una dieta con dosis elevadas de HAP y AHC desarrollaron varios tipos diferentes de cáncer. Por ejemplo, en un estudio publicado en la revista Carcinogenesis (en inglés), los roedores alimentados con AHC en su dieta tenían más probabilidades de desarrollar cáncer de mama y cáncer de colon. Sin embargo, los estudios en seres humanos no han demostrado que los HAP o las AHC causen cáncer, y esta sigue siendo un área de investigación en curso.

El estudio de estas sustancias químicas en humanos es especialmente difícil porque es difícil identificar la cantidad exacta de HAP o AHC que una persona consume basándose en cuestionarios sobre su ingesta diaria de alimentos. Además, los niveles de HAP y de AHC pueden variar según el tipo de carne, la duración de la cocción y la temperatura de cocción. Por último, la forma en que su cuerpo metaboliza estas sustancias químicas o su exposición a estas sustancias químicas en su entorno pueden diferir de la de otra persona. Para algunas personas, esto podría afectar probablemente a su riesgo de desarrollar cáncer.

“No hay una recomendación clara sobre lo que es una cantidad segura (para consumir),” dice Julie Lanford, MPH, RD, CSO, LDN, una dietista registrada y la autora y creadora de CancerDietitian.com. Pero Lanford no recomienda evitar por completo las carnes a la parrilla. En su lugar, aconseja a las personas que cocinan a la parrilla con más frecuencia, como una o dos veces a la semana, que seleccionen diversos alimentos, como verduras, pescado cocido en papel de aluminio o carnes bajas en grasa, para reducir su exposición a HAP y AHC.

Otras formas de reducir posiblemente la exposición a estas sustancias químicas incluyen:

• Intentar evitar las llamaradas que pueden carbonizar la carne
• Precocer parcialmente las carnes para reducir el tiempo en la parrilla
• Marinar la carne previamente para proporcionar una capa protectora contra estas sustancias químicas

cancer.net/sites/cancer.net/files/julie-lanford-circle.png” alt=”” width=”100″ height=”100″/>

“Coma muchas frutas, verduras, cereales integrales, fríjoles, frutos secos y semillas. Si puede equilibrar los alimentos que podrían tener un mayor riesgo de carcinógenos con grandes cantidades de alimentos buenos, saludables y nutritivos, obtendrá el equilibrio adecuado”.–Julie Lanford, MPH, RD, CSO, LDN, una nutricionista registrada y la autora y creadora de CancerDietitian.com

¿Puede la acrilamida causar cáncer?

La acrilamida se identificó por primera vez en alimentos en 2002 (en inglés) y, aunque probablemente no sea una sustancia química nueva, desde entonces han ido aumentando los estudios de sus efectos sobre la salud.

En estudios con animales, se ha descubierto que los niveles altos de acrilamida causan varios tipos de cáncer, según la FDA (en inglés). Sin embargo, los estudios en personas no son concluyentes. Esto podría deberse a la dificultad para calcular el nivel de ingesta de acrilamida en la dieta de una persona. Además, los niveles de acrilamida en los alimentos pueden variar en función de la temperatura de cocción, la duración de la cocción, el almacenamiento de los alimentos y otros factores.

El panel de la Autoridad Europea de Seguridad Alimentaria (en inglés) y la Organización Conjunta de Agricultura y Alimentos de las Naciones Unidas/el Comité Experto de la Organización Mundial de la Salud sobre Aditivos Alimentarios (en inglés) categorizan la acrilamida como una inquietud y recomiendan seguir estudiando el posible riesgo de cáncer en las personas. Mientras tanto, la Agencia Internacional para la Investigación del Cáncer (en inglés) considera que la acrilamida es un probable carcinógeno humano, y el Programa Nacional de Toxicología de los EE. UU. (en inglés) clasifica la acrilamida como “previsto razonablemente como carcinógeno humano”.

La FDA no publica qué niveles de acrilamida son aceptables en una dieta y no aconseja dejar de comer alimentos con acrilamida. En su lugar, se recomienda seguir una dieta equilibrada y saludable que contenga una variedad de verduras, frutas, cereales, productos lácteos sin grasa o bajos en grasa y proteínas.

Sin embargo, si desea reducir la acrilamida en su dieta, la FDA le ofrece estos consejos:

• Tueste el pan hasta que esté de un marrón dorado en lugar de uno oscuro.
• Siga las instrucciones de la etiqueta de los alimentos para freír o cocinar alimentos congelados, como las papas fritas, y evite sobrecocinarlos.
• Almacene las papas en una zona fresca y seca, pero no en el refrigerador; esto puede aumentar la acrilamida durante la cocción.

La información de esta publicación se basa en la investigación actual y en las opiniones de expertos disponibles hoy en día. Estos hallazgos pueden cambiar a medida que surjan más investigaciones sobre este tema.

Each year, cancerCare hosts “Do Something for cancerCare,” an annual DIY event where people create their own fundraising activities to raise money and give back to the organization which impacted their cancer journey, or helped a loved one during their experience.

As we launch this year’s Do Something campaign, we wanted to share a story about a group of young men who are doing something in memory of their friend:

In Fairfield, Connecticut, a group of childhood friends shared an unbreakable bond with Ryan Van Zandt, who was “anything but boring and knew how to entertain those around him,” shared Ryan’s friend, Conor. From childhood to his early twenties, His contagious smile, humor and kindness endeared him to everyone who met him.

It was Ryan’s love of sports and his second diagnosis of a rare form of cancer that led his friends to start “Reps 4 Ryan” in 2015. Combining golf and fitness, the group organized a local golf tournament at the Fairchild Wheeler Golf Course, along with a viral social media challenge.

“Each and every day had more and more people posting pictures and videos of them throwing reps up in the gym in their Reps 4 Ryan gear,” said Conor. This online presence became so large that it eventually caught the attention of a few Miami Dolphins football players, Ryan’s favorite NFL football team.

At only 25 years old, “to see Ryan receive his second diagnosis was not just devastating, but aggravating at the same time. That’s two times too many and two times more than most people have to go through such an experience.”

“All of those horrible feelings were quickly channeled into motivation to act for Ryan and his tremendous family.” Conor added that “as sad of a time as it was for us with Ryan’s health, it was an incredibly special thing to see so many people band together. Short on energy and strength due to his ailing health at the time, Ryan rallied and joined everyone at the course for that first tournament in 2015.”

When Ryan passed away in 2016, his friends channeled their feelings of grief and loss into Reps 4 Ryan, now an annual tradition that continues to make an impact. Drawing over 100+ participants each fall, the funds raised at the tournament go towards cancerCare‘s support services and cancer research. Reps 4 Ryan is no longer just an event – it’s a reunion, a celebration and a way to remember the warmth of their family member and friend. It brings Ryan’s community back each year, honoring his memory and the enduring bonds they share.

Ryan’s mother, Lorette, added that he “inspired more than just the Reps 4 Ryan team.” Two books were actually written about him. “Everyone has grieved in different ways,” she said. “But largely, those around him have found the outlets of continuing to help others and connect more with their community as the most positive and helpful way to confront our devastating loss.”

In honoring Ryan’s spirit, Reps 4 Ryan exemplifies the impact a close-knit community can wield as a force for good. “There’s a tremendous buzz around this tournament for so many people and that buzz is something each of us are proud to be a part of and we’re confident that Ryan would love knowing how much he is still loved and missed by all.”